Matinas BioPharma Holdings (MTNB) Capital Leases (2014 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Capital Leases of $5000.0 for Q1 2026, down 54.55% year-over-year from $11000.0 in Q1 2025, and little changed quarter-over-quarter from $5000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Capital Leases (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Capital Leases for 12 consecutive years, with $5000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Leases fell 54.55% year-over-year to $5000.0; the TTM figure through Mar 2026 stood at $5000.0 (down 54.55% YoY), while the FY2025 annual figure was $5000.0, down 58.33% from the prior year.
- Capital Leases steadied at $5000.0 in Q1 2026 per MTNB's latest filing, from $5000.0 in the prior quarter.
- Across five years, Capital Leases topped out at $22000.0 in Q4 2022 and bottomed at $5000.0 in Q4 2025.
- Historically, Capital Leases has averaged $14285.7 across 5 years, with a median of $14500.0 in 2024.
- Annual changes were most pronounced in 2022 — Capital Leases jumped 633.33% — and 2025, when it sank 58.33%.
- Matinas BioPharma Holdings' Capital Leases stood at $22000.0 in 2022, then dropped by 18.18% to $18000.0 in 2023, then plunged by 33.33% to $12000.0 in 2024, then tumbled by 58.33% to $5000.0 in 2025, then changed by 0.0% to $5000.0 in 2026.
- Business Quant data shows MTNB's Capital Leases at $5000.0 in Q1 2026, $5000.0 in Q4 2025, and $11000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Dec 31, 2024 | 12,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 15,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Mar 31, 2023 | 21,000.00 |
| Dec 31, 2022 | 22,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Sep 30, 2021 | 5,745.00 |
| Jun 30, 2021 | 11,508.00 |
| Mar 31, 2021 | 17,134.00 |
| Dec 31, 2020 | 23,660.00 |